[1] In 1994, the Rockefeller Foundation convened an international meeting of AIDS researchers, vaccinologists, public health officials, and representatives from philanthropic organizations in Bellagio, Italy, to evaluate the challenges facing HIV/AIDS vaccine development and identify ways to jump-start research.

[1] In September 2009, a global group of researchers led by IAVI published a study in the journal Science identifying PG9 and PG16, two highly powerful broadly neutralizing antibodies against a wide variety of HIV variants.

[7] To address major obstacles in AIDS vaccine development, IAVI partners with HIV researchers from around the world.

[2] It also partners with civil society organizations and other entities to advocate jointly for the development of AIDS vaccines, and is a member of the Global Health Technologies Coalition, an alliance of more than 30 non-profit groups that aims to increase awareness of the urgent need for technologies that save lives in developing countries.

[8] IAVI's work is funded by donors including: the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations, the Ministry of Foreign Affairs of Denmark, Irish Aid, the Ministry of Finance of Japan in partnership with The World Bank, the Ministry of Foreign Affairs of the Netherlands, the United Kingdom Department for International Development, and the United States Agency for International Development (USAID).